Navigating 7 Analyst Ratings For Stryker

7 analysts have shared their evaluations of Stryker SYK during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $324.57, a high estimate of $345.00, and a low estimate of $297.00. Witnessing a positive shift, the current average has risen by 10.1% from the previous average price target of $294.80.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Stryker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Stryker's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Stryker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Stryker analyst ratings.

Unveiling the Story Behind Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Unraveling the Financial Story of Stryker

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Positive Revenue Trend: Examining Stryker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.6% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Stryker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.1%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Stryker's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.92%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Stryker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.83% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0.71, Stryker adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.